Kacharava A G, Tertov V V, Zhukova I M, Orekhov A N
Kardiologiia. 1992 Jun;32(6):21-3.
The serum atherogenic potential in patients with coronary heart disease (CHD) concurrent with hypercholesterolemia (LDL cholesterol more than 200 mg/dl), which is able to cause accumulation of intracellular cholesterol in cultured cells has been recently shown to be directly related to the level of total cholesterol and LDL cholesterol. The study was undertaken to examine how a lovastatin-induced decrease in LDL levels affects serum atherogenicity in patients with CHD and hypercholesterolemia. It was shown that the therapy of 22 patients with CHD and hypercholesterolemia led to a reduction in total and LDL cholesterol levels on an average by 24% and 32%, respectively. There were 3- and 1.5-2-fold decreases in circulatory immune complexes and the atherogenic potential, respectively. The findings suggest that the significant reduction in serum LDL cholesterol levels in patients with CHD concurrent with hypercholesterolemia who take hypolipidemic therapy is followed by a decrease in the atherogenic potential.
冠心病（CHD）合并高胆固醇血症（低密度脂蛋白胆固醇超过200mg/dl）患者的血清致动脉粥样硬化潜能，能够导致培养细胞内胆固醇蓄积，最近研究表明其与总胆固醇和低密度脂蛋白胆固醇水平直接相关。本研究旨在探讨洛伐他汀引起的低密度脂蛋白水平降低如何影响冠心病合并高胆固醇血症患者的血清致动脉粥样硬化性。结果显示，22例冠心病合并高胆固醇血症患者接受治疗后，总胆固醇和低密度脂蛋白胆固醇水平平均分别降低了24%和32%。循环免疫复合物和致动脉粥样硬化潜能分别降低了3倍和1.5 - 2倍。研究结果表明，接受降脂治疗的冠心病合并高胆固醇血症患者血清低密度脂蛋白胆固醇水平显著降低后，其致动脉粥样硬化潜能也随之降低。
